254
Views
3
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Outcome and prognosis of anaplastic large cell lymphoma in children: a report from the Taiwan Pediatric Oncology Group

ORCID Icon, , ORCID Icon, ORCID Icon, , , ORCID Icon, , ORCID Icon, , , , ORCID Icon & show all
Pages 1942-1949 | Received 05 Jun 2018, Accepted 05 Dec 2018, Published online: 15 Jan 2019
 

Abstract

Studies of childhood anaplastic large cell lymphoma (ALCL) are less reported from East Asian countries. Clinical features and outcome of 90 children with ALCL in Taiwan were analyzed. The median age at diagnosis was 11.7 years. The most common presentation was lymph node involvement (86.7%). Advanced diseases accounted for 70% of patients at diagnosis. Most patients (93.1%) had positive staining for anaplastic lymphoma kinase. The five-year overall survival and event-free survival (EFS) rates were 79.7% and 73.3%, respectively. Bone marrow involvement, advanced stage, and thoracopulmonary ALCL were adverse prognostic factors for EFS (p=.05, .04, and .03, respectively). In multivariate analysis, only thoracopulmonary ALCL had a marginal significance on worse EFS (p= .054). We suggested that children with thoracopulmonary ALCL may need to intensify the treatment, and introduction of new targeted therapies for relapsed/refractory disease will be required.

Acknowledgements

We express our sincere gratitude to all physicians from 24 participating hospitals who helped take care of these patients. We also thank the Data Managers of the Biostatistical Center, the Childhood Cancer Foundation of the ROC, Taiwan, for their assistance.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2018.1562182.

Additional information

Funding

This work was partially supported by the grant CORPG3E0022 from Chang Gung Memorial Hospital, Taiwan, the grants 104-2314-B-182A-116, 105-2314-B-182A-116 and 106-2314-B-182A-143-MY2 from the Ministry of Science and Technology, Taiwan, and the Childhood Cancer Foundation of the ROC, Taiwan.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.